2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.65 (Poster) Efficacy and Safety of Dose-Escalated Alectinib in Patients with Metastatic ALK-positive NSCLC and CNS Relapse on Standard Dose Alectinib

PP01.65 (Poster) Efficacy and Safety of Dose-Escalated Alectinib in Patients with Metastatic ALK-positive NSCLC and CNS Relapse on Standard Dose Alectinib

Back to course

Pdf Summary

A recent study investigated the efficacy and safety of dose-escalated alectinib in patients with metastatic ALK-positive non-small cell lung cancer (NSCLC) and central nervous system (CNS) relapse on standard dose alectinib. The study found that dose-escalated alectinib was well tolerated, with no drug discontinuation due to treatment-related adverse events and no grade 3 or higher adverse events reported. Patients who progressed on dose-escalated alectinib were able to receive subsequent lorlatinib with durable clinical benefit. <br /><br />The study analyzed the baseline characteristics of 27 patients who had advanced ALK-positive NSCLC with CNS relapse on standard dose alectinib. The most common treatment-related adverse events were anemia, fatigue, and constipation. <br /><br />The results showed that dose-escalated alectinib demonstrated clinically meaningful efficacy in patients with CNS relapse. The CNS objective response rate was 25%, and the CNS disease control rate was 100%. The median duration of dose-escalated alectinib therapy was 7.7 months, with median CNS time to progression of 7.1 months. <br /><br />Furthermore, the study found that patients who received lorlatinib after treatment failure on dose-escalated alectinib had a median duration of lorlatinib therapy of 41.3 months, with a median CNS time to progression of 35.2 months. <br /><br />Overall, the findings suggest that dose-escalated alectinib can be effective and safe in patients with metastatic ALK-positive NSCLC and CNS relapse. The study also showed that subsequent treatment with lorlatinib can provide prolonged clinical benefit in patients who progress on dose-escalated alectinib.

Asset Subtitle

Justin Cheung

Keywords

dose-escalated alectinib

metastatic ALK-positive non-small cell lung cancer

central nervous system relapse

standard dose alectinib

treatment-related adverse events

lorlatinib

baseline characteristics

anemia

fatigue

constipation